Clinical trial · no report yet · Phase 2
NCT03639935
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
- NCT03639935 ↗
- Completed
- University of Michigan Rogel Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Biliary Tract Cancer
- Interventions
- Rucaparib; Nivolumab
- Arms
- Rucaparib and Nivolumab · Experimental
- Enrollment
- 32
- Primary outcomes
- Proportion of Patients Alive and Without Radiological or Clinical Progression at 4 Months
- Sponsor
- University of Michigan Rogel Cancer Center with Dana-Farber Cancer Institute, Vanderbilt University Medical Center
- Start
- Mar 28, 2019
- Primary completion
- Feb 7, 2023
- Results posted
- Yes
- Registry record
- NCT03639935 · updated Jun 3, 2025
Publications
linked from the registry- Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V. A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02. Clin Cancer Res. 2026 Jul 23. doi: 10.1158/1078-0432.CCR-25-1114. Online ahead of print. PubMed 42489677